Terms: = Prostate cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Prognosis
32 results:
1. A novel tumor purity and immune infiltration-related model for predicting distant metastasis-free survival in prostate cancer.
Su Q; Zhu Y; He B; Dai B; Mu W; Tian J
Eur J Med Res; 2023 Nov; 28(1):545. PubMed ID: 38017548
[TBL] [Abstract] [Full Text] [Related]
2. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for prostate cancer Therapy.
Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
Mol Pharm; 2023 Nov; 20(11):5921-5936. PubMed ID: 37874541
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive analysis of integrin αvβ3/α6β1 in prognosis and immune escape of prostate cancer.
Liu Y; He JX; Ji B; Wang JF; Zhang L; Pang ZQ; Wang JS; Ding BC; Ren MH
Aging (Albany NY); 2023 Oct; 15(20):11369-11388. PubMed ID: 37862114
[TBL] [Abstract] [Full Text] [Related]
4. The prognosis-Predictive and Immunoregulatory Role of SUMOylation Related Genes: Potential Novel Targets in prostate cancer Treatment.
Sun JX; An Y; Xiang JC; Xu JZ; Hu J; Wang SG; Xia QD
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686409
[TBL] [Abstract] [Full Text] [Related]
5. Membrane tension-mediated stiff and soft tumor subtypes closely associated with prognosis for prostate cancer patients.
Feng D; Wang J; Shi X; Li D; Wei W; Han P
Eur J Med Res; 2023 May; 28(1):172. PubMed ID: 37179366
[TBL] [Abstract] [Full Text] [Related]
6. Integrated analysis of single-cell and bulk RNA sequencing identifies a signature based on macrophage marker genes involved in prostate cancer prognosis and treatment responsiveness.
Li X; Zheng C; Xue X; Wu J; Li F; Song D; Li X
Funct Integr Genomics; 2023 Apr; 23(2):115. PubMed ID: 37010617
[TBL] [Abstract] [Full Text] [Related]
7. Old and New Blood Markers in Human Colorectal cancer.
Wautier JL; Wautier MP
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361758
[TBL] [Abstract] [Full Text] [Related]
8. The Oncogenic and Immunological Roles of Apoptosis Antagonistic Transcription Factors in Human Tumors: A Pan-cancer Analysis.
Lu F; Wu J; Zou H; Yang X; Wu Y; Xu J
Oxid Med Cell Longev; 2022; 2022():3355365. PubMed ID: 36275893
[TBL] [Abstract] [Full Text] [Related]
9. Identification of LAT/ZAP70 characterized immune subtypes of prostate cancer.
Yu J; Gao W; Gao S; Wen S; Zhao Y; Shang Z; Wang Y; Niu Y
World J Urol; 2022 Nov; 40(11):2817-2824. PubMed ID: 36205741
[TBL] [Abstract] [Full Text] [Related]
10. Comprehensive Analysis of m5C Methylation Regulatory Genes and Tumor Microenvironment in prostate cancer.
Yu G; Bao J; Zhan M; Wang J; Li X; Gu X; Song S; Yang Q; Liu Y; Wang Z; Xu B
Front Immunol; 2022; 13():914577. PubMed ID: 35757739
[TBL] [Abstract] [Full Text] [Related]
11. Characterization of a Pyroptosis-Related Signature for prognosis Prediction and Immune Microenvironment Infiltration in prostate cancer.
Zhang G; Luo Y; Dong W; Zhong W
Comput Math Methods Med; 2022; 2022():8233840. PubMed ID: 35516457
[TBL] [Abstract] [Full Text] [Related]
12. Smartphone-Based Electrochemical Biosensors for Directly Detecting Serum-Derived Exosomes and Monitoring Their Secretion.
Su J; Chen S; Dou Y; Zhao Z; Jia X; Ding X; Song S
Anal Chem; 2022 Feb; 94(7):3235-3244. PubMed ID: 35084842
[TBL] [Abstract] [Full Text] [Related]
13. A novel immune-related gene-based prognostic signature to predict biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Lv D; Wu X; Chen X; Yang S; Chen W; Wang M; Liu Y; Gu D; Zeng G
Cancer Immunol Immunother; 2021 Dec; 70(12):3587-3602. PubMed ID: 33934205
[TBL] [Abstract] [Full Text] [Related]
14. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract] [Full Text] [Related]
15. Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Armstrong AJ; Nixon AB; Carmack A; Yang Q; Eisen T; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; George DJ; Halabi S
Clin Cancer Res; 2021 Jun; 27(12):3317-3328. PubMed ID: 33593885
[TBL] [Abstract] [Full Text] [Related]
16. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer.
Karpisheh V; Mousavi SM; Naghavi Sheykholeslami P; Fathi M; Mohammadpour Saray M; Aghebati-Maleki L; Jafari R; Majidi Zolbanin N; Jadidi-Niaragh F
Life Sci; 2021 Nov; 284():119132. PubMed ID: 33513396
[TBL] [Abstract] [Full Text] [Related]
17. [Advances in immunotherapy of extranodal NK/T cell lymphoma].
Hao DQ; Li LQ; Li MC; Gong LL
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Dec; 54(12):949-953. PubMed ID: 31887826
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic Value of
Lee CH; Chen LC; Yu CC; Lin WH; Lin VC; Huang CY; Lu TL; Huang SP; Bao BY
Int J Environ Res Public Health; 2019 Nov; 16(23):. PubMed ID: 31783478
[TBL] [Abstract] [Full Text] [Related]
19. Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in prostate cancer.
Richardsen E; Andersen S; Al-Saad S; Rakaee M; Nordby Y; Pedersen MI; Ness N; Ingebriktsen LM; Fassina A; Taskén KA; Mills IG; Donnem T; Bremnes RM; Busund LT
Sci Rep; 2019 Jul; 9(1):10662. PubMed ID: 31337863
[TBL] [Abstract] [Full Text] [Related]
20. Microarray-based data mining reveals key genes and potential therapeutic drugs for Cadmium-induced prostate cell malignant transformation.
Xiang Y; Zhang L; Huang Y; Ling J; Zhuo W
Environ Toxicol Pharmacol; 2019 May; 68():141-147. PubMed ID: 30897525
[TBL] [Abstract] [Full Text] [Related]
[Next]
